TheProfitWatch

CTOR - Citius Oncology, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
1.19 -0.06 (-5.04%) --- --- 0.0 (0.0%) -0.05 (-4.2%) -0.02 (-1.74%) --- -0.05 (-4.2%)

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.08
Diluted EPS:
-0.08
Basic P/E:
-14.125
Diluted P/E:
-14.125
RSI(14) 1m:
45.37
VWAP:
1.13
RVol:

Events

Period Kind Movement Occurred At

Related News